Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cutaneous and systemic treatment-related adverse events as prognostic markers in immunotherapy and targeted therapy, with a focus on melanoma.

Created on 17 Nov 2026

Authors

Orsola Crespi, Umberto Santaniello, François Rosset, Valentina Pala, Simone Ribero, Pietro Quaglino

Published in

Italian journal of dermatology and venereology. Volume 161. Issue 5. Pages 487-496.

Abstract

Immune checkpoint inhibitors (ICIs) and targeted therapies have transformed the management of advanced malignancies but are associated with characteristic adverse events (AEs), many of which are skin-predominant. Increasing evidence indicates that selected treatment-related AEs, particularly immune-related adverse events (irAEs) and on-target toxicities, may serve as dynamic biomarkers of antitumor activity. This review summarizes current data on the incidence, spectrum, and prognostic significance of irAEs and targeted-therapy AEs, with a specific emphasis on cutaneous events relevant to dermatologists. We highlight the robust association between cutaneous irAEs (cirAEs) - including vitiligo, regression of melanocytic nevi and halo phenomena in melanoma - and improved clinical outcomes. We also examine prognostic data for other cutaneous patterns (lichenoid, psoriasiform, bullous), endocrine and other organ-specific irAEs, and on-target dermatologic toxicities under epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR), and BRAF/MEK inhibition. Finally, we discuss mechanistic hypotheses and practical implications for dermatology practice, stressing the need to balance recognition of toxicity as a favorable biomarker with timely management to avoid treatment interruption.

PMID:
43043303
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement